Search

Search Constraints

You searched for: Author/Creator Harrow, Stephen

Search Results

1. 92 Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-COMET. (October 2019)

2. Lung cancer symptom appraisal among people with chronic obstructive pulmonary disease: A qualitative interview study. Issue 4 (12th February 2019)

3. 91 Quality of Life Outcomes After Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial. (October 2019)

4. 23: Cost-Effectiveness of Sabr in Oligometastatic Cancer: An Economic Analysis Based on Long-Term Results of the SABR-Comet Randomized Trial. (October 2021)

7. CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). (March 2022)

8. Gross tumour volume predicts survival and correlates with pre-treatment serum albumin concentration in patients with stage III non-small cell lung cancer treated with chemo-radiotherapy. (March 2022)

9. Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy. (March 2022)

10. Adjuvant durvalumab post-chemoradiotherapy in stage III non-small cell lung cancer: experience from the Edinburgh Cancer Centre. (March 2022)